COSMECA Korea announced on the 10th that its consolidated revenue for Q1 2026 reached 185.1 billion KRW, marking a 56.4% increase from the previous year. The company also reported an operating profit of 21.88 billion KRW, reflecting a 78.0% rise year-over-year, and a net income of 19.62 billion KRW, up 112.8%. The consistent growth trajectory highlights the strategic shifts enacted by the company across its operations.

The strong performance in the Korean subsidiary, which recorded revenue of 142.2 billion KRW—a 91.3% increase year-on-year—was propelled by the diversification of its K-beauty indie brand clientele and expanded global exports. Notably, skincare revenues surged by 106.5%, cementing this segment's role as a critical growth driver. Additionally, the sun care category experienced a remarkable increase of 173.6%, transcending seasonal trends to establish itself as a significant growth area. The introduction of new product categories, such as hydrogel masks, further enhances COSMECA's growth potential.

Meanwhile, the U.S. subsidiary, Inglewood Lab, reported Q1 revenue of 49.7 billion KRW, up 16.9% from the prior year. The skincare segment saw a 25.3% increase, reflecting a solid growth foundation. Particularly, the dual production strategy responding to customs issues for K-beauty brands in partnership with New Jersey’s Totowa has strengthened sales through legacy brand transitions.

Despite facing challenges, COSMECA China experienced a revenue decline of 27.1% year-over-year, generating 6.4 billion KRW. Delays in securing raw materials and changes in sub-supplier relationships have impacted sales timelines. Nevertheless, the company aims to enhance supply chain responsiveness while diversifying its portfolio with a focus on color cosmetics such as lip products, blushers, and concealers, alongside strategic offerings in cushions and sun sticks.

Looking ahead, COSMECA Korea plans to pursue growth and profitability simultaneously in the second half of 2026. The company aims to enhance its collaboration with global clients by leveraging its formulation development capabilities, rapid product proposition speed, production flexibility, and quality competitiveness, aligning with K-beauty brands' increasing international demand.

In March, COSMECA increased its stake in Inglewood Lab from 50.0% to 66.7% through a public purchase, reinforcing its control over U.S. operations and operationalizing its dual production strategy. This move is poised to bolster its competitive edge within the North American ODM market.

A spokesperson for COSMECA Korea commented, "Thanks to the balanced growth of our Korean and American subsidiaries, both revenue and profitability have improved. We will fortify our mid-to-long-term growth foundation through customer portfolio diversification and enhanced technological capabilities alongside elevated global production strategies."